KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Expenses: 2009-2024

Historic Operating Expenses for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $2.2 billion.

  • Teva Pharmaceutical Industries' Operating Expenses rose 6.51% to $573.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year increase of 4.04%. This contributed to the annual value of $2.2 billion for FY2024, which is 2.08% up from last year.
  • Teva Pharmaceutical Industries' Operating Expenses amounted to $2.2 billion in FY2024, which was up 2.08% from $2.1 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Operating Expenses ranged from a high of $2.2 billion in FY2020 and a low of $2.0 billion during FY2022.
  • In the last 3 years, Teva Pharmaceutical Industries' Operating Expenses had a median value of $2.1 billion in 2023 and averaged $2.1 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Operating Expenses dropped by 4.79% in 2021, and later rose by 4.81% in 2023.
  • Teva Pharmaceutical Industries' Operating Expenses (Yearly) stood at $2.2 billion in 2020, then fell by 4.79% to $2.1 billion in 2021, then decreased by 2.32% to $2.0 billion in 2022, then rose by 4.81% to $2.1 billion in 2023, then rose by 2.08% to $2.2 billion in 2024.